Clinical Trials Search at Vanderbilt-Ingram Cancer Center

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Multiple Cancer Types

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity
of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after
lymphodepletion consisting of cyclophosphamide and fludarabine.

Disease Sites: Lymphoma, Phase I

Phase: I

Investigator: Oluwole, Olalekan

NCTID: NCT04637763

Protocol No: VICC-DTCTT23155P

Learn More

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Multiple Cancer Types

Clinical Trial Flowcharts
for Referring Physicians

Clinical Trial Flowcharts
for VICC Staff (VUNetID required)

Clinical Trials Search CTA Inline Referral Form

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Multiple Cancer Types

Clinical Trial Flowcharts for Referring Physicians

Clinical Trial Flowcharts for VICC Staff (VUNetID required)

Clinical Trials Search CTA Inline Referral Form

Clinical Trial Flowcharts
for Referring Physicians

Clinical Trial Flowcharts
for VICC Staff (VUNetID required)